Meeting
2024 ASCO Gastrointestinal Cancers Symposium
A phase I clinical trial of riluzole in combination with mFOLFOX6 and bevacizumab in treating patients with metastatic colorectal cancer.
Authors
Chunjie Li
The Ohio State University Wexner Medical Center, Columbus, OH
Chunjie Li , Anne M. Noonan , John L. Hays , Sameek Roychowdhury , Pannaga G. Malalur , Rifat T. Elkhatib , Ashish Manne , Arjun Mittra , Shafia Rahman , Mitch A. Phelps , Beiyuan Liang , Hadyen Storts , Misbah Khan , Evan Zhang , Xinru Zheng , Wayne Miles , Jing Wang , Ning Jin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04761614
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 101)
DOI
10.1200/JCO.2024.42.3_suppl.101
Abstract #
101
Poster Bd #
G5
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab: Results of the expansion part of a phase I study in patients with metastatic colorectal cancer.
First Author: Roberto Bordonaro
Poster
2019 Gastrointestinal Cancers Symposium
A phase I study of TAS-102 in combination with oxaliplatin (TAS-OX) for refractory metastatic colorectal cancer (mCRC).
First Author: Michael Cecchini
Poster
2015 Gastrointestinal Cancers Symposium
Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC).
First Author: Johanna C. Bendell
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC).
First Author: Fuxiang Zhou